AiViva
OperatingAiViva Holding Limited
Biotech · Biotech · Newport Beach, CA · Founded 2020
Developing treatments that change lives
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
“Today's shares” restates every price in the share terms current now, so a price before a split or an LLC→corporation conversion is divided by that event's ratio (each event is cited on the round page). Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines, and each class is drawn as its own line.
Cap table
Share counts as of Dec 31, 2022| Class | Outstanding | Votes / share | Share of total | Liquidation | Last price |
|---|---|---|---|---|---|
| Series A-1 Preferred Stockpreferred | 4,693,227 | 1 | 18.2% | 1× · paid 1st | $9.93Jan 2022 |
| Series A Preferred Stockpreferred | 8,213,831 | 1 | 31.9% | 1× · paid 2nd | $9.92Jan 2019 |
| Common Stock | 12,853,068 | 1 | 49.9% | paid 3rd | $1.65Apr 2023 |
| Total | 25,760,126 | 100% |
Principal holders% as the filing states it, Apr 30, 2025
- TCL 2015 LIC managed by Diane Tang-Liu7,078,920 Common Stock24.6%of
Sold to the crowd
- Reg CF · Jun 2022364,005 shares at $2.00$728K· 423 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
14 people
Co-founder, CEO and Board Director, AiViva BioPharma, Inc. Co-founder, Allgenesis, Inc. Previously Diane has held various senior executive positions at Allergan, Inc. where she built and led R&D programs for 30 years. She is a full adjunct professor of Pharmacology and Pharmaceutical Sciences and Regulatory and Quality Sciences at the University of Southern California and served as a full adjunct professor of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. She published extensively and holds many patents. Diane received many awards and is Elected fellow, American Association of Pharmaceutical Scientists and American College of Clinical Pharmacology.
Dr. Deecher has more than 25 years of clinical development and pharmaceutical commercialization. She has led therapeutic portfolios in 3 major drug development sectors including Fortune 500-Pharmaceutical Companies. At Covance she was the strategic leader for phase II-IV trials/programs. She was Senior Vice President of Research, Development and Advocacy at a leading patient organization, the Juvenile Diabetes Research Foundation (JDRF) and led the women’s health research and development programs at Wyeth Pharmaceuticals (Pfizer) for over 15 years.
Mr. Cerrato has 20+ years of experience in life sciences encompassing, pharmaceutical, biotechnology and medical device space; with, successful leadership disciplines in corporate and business development, global commercial development, product launches, investor relations, strategic marketing and sales management. He has raised capital from international venture capital firms, closed strategic deals with large and small cap companies and led alliance management in cross-functional objectives. He has held progressive leadership positions at Solva Holdings, Bausch + Lomb, Allergan, Valeant Pharmaceuticals, Serono Biotech, Salu Inc., and Pfizer Pharmaceuticals. He honorably served in the United States Marine Corps with multiple combat deployments in Desert Shield and Desert Storm, and was an elite triathlete competing in Ironman distances including the World Championship in Hawaii. Mr. Cerrato works full-time as an independent contractor for the Company.
Hannah Hershoff M.D., Ph.D. is a neuro-ophthalmologist with over 30 years of clinical and drug development experience. Before joining AiViva Biopharma, Inc., she served as Chief Medical Officer at Longwood Pharmaceuticals, Inc. Prior to her medical leadership role at Longwood Pharmaceuticals, Inc., Dr. Hershoff was President and Co-owner of MYAD Consultant Group, where she supervised clinical and development strategy. Before her pharmaceutical industry experience, Dr. Hershoff was a senior ophthalmologist, eye surgeon, and physician-in-charge at Zhongshan Eye Hospital, Guangzhou, China. Prior to becoming an ophthalmologist, she practiced as a neurologist at Nanchang First Hospital, China. She is an inventor and author of more than 20 patents and publications in the field of Ophthalmology and Neurology. Dr. Hershoff received her M.D. from Jiangxi Medical School, China, Ph.D. in Experimental Ophthalmology from Lund University, Sweden, and Post-Doctoral Fellowship from Harvard Medical School. She also received her M.S. in Neurology from Sun Yat-sen University Zhongshan Medical School, China.
Jinn was Founder and President of XenoBiotic Laboratories, Inc. (XBL) and XBL-China in Nanjing, China. He served as Adjunct Professor at the University of Medicine and Dentistry of New Jersey (UMDNJ at Rutgers) and Adjunct Professor at The Hong Kong Polytechnic University.
Mr. Jung-Chin (Rongjin) Lin has held several chief executive management roles in various pharmaceutical companies over the past 30 years. Mr. Lin’s specialty is strategic management for pharmaceutical and biotech industries and specializes in company restructuring, building pharmaceutical business strategies and establishing strategic management. He has successfully restructured and reorganized over 15 enterprises and is still actively engaged in distributing and integrating related investments in the biotech industry. Mr. Lin is currently Honorary President of Center Laboratories, Inc. and Chairman of Lumosa Therapeutics Co., Ltd. in Taiwan. Mr. Lin transformed Center Labs from a multiple-dosage pharmaceutical company into a professional oral solution pharmaceutical, which drives over 70% market shares in Taiwan. In recent years, Center Labs, Inc. played a role as an Industrial Biotech Bank platform, which targets to invest and integrate more biotech companies. The new investing fields include new drug development, antibody engineering and protein design, cell line generation, biosimilar drug development and production, medical devices, nutrition, and agricultural biotech; investing regions cover the Greater China Region and other Asian countries such as Japan and Korea. In late 2014, Center Labs Inc. also acquired Ausnutria Dairy Corp, expanding the investment in the infant formula industry. Mr. Lin received his B.S. degree in Pharmacy from the School of Pharmacy, Taipei Medical University, and was awarded Doctorate of Philosophy, Honoris Causa by Taipei Medical University in 2010.
Larry was Co-Founder, President and CEO of Impax Laboratories (IPXL) and led a reverse acquisition (1999). IPXL was listed in Nasdaq with a market cap of about $3 billion at the time of his retirement from the Impax. Chairman & CEO, LifeMax Healthcare International. Chairman & CEO, AmMax Bio. Chairman & CEO, LifeMax Labs. Chairman & CEO, LifeMax Biotechnology (Taiwan). Under his leadership, Impax established partnerships with multiple companies including Teva, AstraZeneca, Pfizer and Shire. LifeMax Labs currently has a partnership with Novartis. AmMax Bio currently has a partnership with Amgen.
Show 5 more peopleShow fewer
Les Kaplan, PhD, has served on Nicox’ board of directors since October 2014. He was the executive chairman of Aciex Therapeutics, Inc., a pharmaceutical development company in ophthalmology acquired by Nicox in October 2014. He is an independent board member of Beacon Therapeutics. Dr. Kaplan began his career at Allergan Inc., where he served as the Executive Vice President and President, Research & Development and Global Botox, and a board member of Allergan. During his tenure heading Allergan's R&D function more than 20 major pharmaceutical products and new indications were approved by the FDA, the European Union, Japan and major Ministries of Health around the world. Prior to joining Allergan, Dr. Kaplan held research positions at the Upjohn Company and at the University of California, Los Angeles. He previously served as a member of the board of directors of Acadia Pharmaceuticals, Acucela Inc., Altheos (Executive Chair), Neurotech, Oculex and National Neurovision Research Institute (FFB). Dr. Kaplan received a Ph.D. in organic chemistry from the University of California, Los Angeles.
Dr. Ding has more than 35 years of drug development and regulatory experience and has been a trailblazer in ophthalmic formulation development. She was Senior Formulation Scientist, Allergan Inc. and was the patent inventor for Restasis, a product achieving over $1 billion in annual sales. Later at Trimeris, Inc., she was responsible for pharmaceutical development of Fuzeon®, a lyophilized parenteral product approved in 2003 by the FDA for the treatment of HIV-1 infection. She was a CMC lead reviewer with the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) for 13 years.
Dr. Zhao has more than 20 years of applied research experience in translating drug discovery findings to support human clinical testing. He held various scientific positions at Allergan and Vitae Pharmaceuticals. His effects led to clinical development of P450 RAI Inhibitor, 11β-HSD1 inhibitor, BACE inhibitor, RORγt inverse agonist, selective LXRβ agonist, and menin inhibitor for the treatment of dermatological, Type 2 diabetes, Alzheimer’s, auto immune disorders, and leukemias.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 12 filings on EDGAR- Form C-TRJul 22, 20260001928381-26-000011EDGAR
- Form C-TRJun 17, 20260001928381-26-000008EDGAR
- Form C-TRApr 16, 20260001928381-26-000005EDGAR
- Form C-ARApr 30, 20250001665160-25-000889EDGAR
- Form C-ARMay 6, 20240001665160-24-000795EDGAR
- Form C-ARApr 28, 20230001665160-23-000947EDGAR
- Form C-UDec 20, 20220001665160-22-003098EDGAR
- Form C/AOct 13, 20220001665160-22-002761EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.